Shopping Cart
- Remove All
Your shopping cart is currently empty
HTH-01-091
HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor (IC50: 10.5 nM) that also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK, and CLK2. It can be used to study breast cancer.
Catalog No. T24152Cas No. 2000209-42-5
Select Batch
Purity:98.40%
Contact us for more batch information
HTH-01-091
Catalog No. T24152Alias HTH01-091, HTH-01091, HTH 01-091, HTH 01091Cas No. 2000209-42-5
HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor (IC50: 10.5 nM) that also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK, and CLK2. It can be used to study breast cancer.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. 
Product information is being updated, if you want to purchase, please click the bulk custom button.
Bulk & Custom
Questions
View MoreInhibitors Related to "HTH-01-091"
Abemaciclib
Cited
LY2835219, CDK4/6 dual inhibitor
T23811231929-97-7
Abemaciclib (LY2835219) is a dual inhibitor of CDK4/6 (IC50=2/10 nM) with selectivity and specificity. Abemaciclib has antitumor activity and is used to treat advanced or metastatic breast cancer.
- $48
Size
QTY
CitedSodium Oxamate Cited
SO, Oxamic acid sodium salt, oxamate sodium, Aminooxoacetic acid sodium salt
T19831565-73-1
Sodium Oxamate (Oxamic acid sodium salt) is an LDH inhibitor that specifically inhibits LDHA. Sodium Oxamate has antitumor activity and induces cell cycle arrest and apoptosis.
- $31
Size
QTY
CitedOditrasertib
DNL-788
T697262252271-93-3
Oditrasertib (DNL-788) is a potent RIPKl inhibitor with an IC50 value of less than 100 nM.Oditrasertib can be used for the study of immune and neurological disorders such as multiple sclerosis and Alzheimer's disease.
Inquiry
Ribociclib Cited
LEE011
T61991211441-98-3
Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor (IC50：10/39 nM).
- $36
Size
QTY
CitedCASIN
Pirl1-related Compound 2
T3971425399-05-9
CASIN (Pirl1-related Compound 2) is a specific inhibitor of GTPase Cdc42 (IC50: 2 uM).
- $32
Size
QTY
Benzamidine hydrochloride
Benzamidine HCl
T83621670-14-0
Benzamidine hydrochloride (Benzamidine HCl) is a reversible inhibitor of serine proteases, including trypsin, plasmin, and thrombin (Ki of 35, 350, and 220 μM, respectively).
- $40
Size
QTY
Palbociclib Cited
PD 0332991
T1785571190-30-2
Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has investigational potential for use in ER-positive and HER2-negative breast cancer.
- $48
Size
QTY
CitedDinaciclib Cited
SCH 727965, PS-095760
T1912779353-01-4
Dinaciclib (SCH 727965) is a selective CDK inhibitor targeting CDK1, CDK2, CDK5, and CDK9 (IC50 = 3/1/1/4 nM). It exhibits potential antitumor activity by inhibiting the incorporation of thoracic glycan (dThd) DNA.
- $47
Size
QTY
CitedCamostat mesylate Cited
FOY-S980, FOY305, Camostat mesilate
T239159721-29-8
Camostat mesylate (FOY-S980) is a trypsin-like protease inhibitor and inhibits airway epithelial sodium channel (ENaC) function.
- $43
Size
QTY
CitedAbemaciclib methanesulfonate Cited
LY2835219 mesylate, LY2835219 (methanesulfonate), LY2835219, abemaciclib mesylate
T31111231930-82-7
Abemaciclib methanesulfonate (LY2835219) is a specific and effective inhibitor of CDK4(IC50=2 nM) and CDK6(IC50=10 nM).
- $30
Size
QTY
CitedPalbociclib monohydrochloride
PD 0332991 hydrochloride, Palbociclib hydrochloride, Palbociclib (PD-0332991) HCl
T6239827022-32-2
Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.
- $30
Size
QTY
Nafamostat mesylate Cited
FUT-175
T239282956-11-4
Nafamostat mesylate (FUT-175), a synthetic serine protease inhibitor, has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
- $39
Size
QTY
CitedProduct Introduction
Bioactivity
Chemical Properties
| Description | HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor (IC50: 10.5 nM) that also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK, and CLK2. It can be used to study breast cancer. |
| Targets&IC50 | DYRK4:41.8 nM, mTOR:632 nM, CDK7:1230 nM, Pim1:60.6 nM |
| In vitro | HTH-01-091 (0-10 μM, 1 h) dose-dependently decreased MELK pull-down by streptavidin beads, demonstrating that the compound is cell permeable and binds to MELK in an ATP-competitive fashion causes MELK degradation.[1] HTH-01-091 (1 μM) selectively inhibits 4% of the kinases over 90%[1]. HTH-01-091 (0-10 μM, 3 days) exhibits minor antiproliferative effects in breast cancer cells[1]. |
| Alias | HTH01-091, HTH-01091, HTH 01-091, HTH 01091 |
| Molecular Weight | 499.43 |
| Formula | C26H28Cl2N4O2 |
| Cas No. | 2000209-42-5 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
| Solubility Information | DMSO: 5 mg/mL (10 mM)  | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy HTH-01-091 | purchase HTH-01-091 | HTH-01-091 cost | order HTH-01-091 | HTH-01-091 chemical structure | HTH-01-091 in vitro | HTH-01-091 formula | HTH-01-091 molecular weight
- TOP
Feedback
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.